Legend Biotech to Host 2022 R&D Day on Monday, October 3, 2022
Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Neutral)
Tags
conferences
Rhea-AI Summary
Legend Biotech Corporation (NASDAQ: LEGN) will host its in-person and virtual Research & Development Day on October 3, 2022, at 10:00 a.m. ET in New York City. The event aims to provide a comprehensive overview of the company's platforms and pipeline developments from its senior leadership team, including CEO Ying Huang and other key executives. A live webcast will be accessible, with a replay available within 24 hours post-event. Investors can register here.
Positive
None.
Negative
None.
Insights
Analyzing...
SOMERSET, N.J.--(BUSINESS WIRE)--
Legend Biotech Corporation (NASDAQ: LEGN) (Legend Biotech), a global biotechnology company developing, manufacturing and commercializing novel therapies to treat life-threatening diseases, today announced it will host its in-person and virtual Research & Development Day on Monday, October 3, 2022 at 10:00 a.m. ET at Andaz 5th Avenue in New York City. Please click here to register for the event.
The event will feature a comprehensive overview of our platforms and the latest developments in our pipeline through presentations from members of Legend’s senior leadership team:
Ying Huang, Ph.D., Chief Executive Officer
Guowei Fang, Ph.D., Senior Vice President, Global Head of Research and Early Development
Lida Pacaud, M.D., Vice President, Clinical Development
Steve Gavel, Vice President, Commercial Development, US & Europe
A live webcast and presentation will be available to investors and other interested parties on the Legend Biotech website under “Events and Presentations”. A replay of the webcast can be viewed as early as 24 hours after the event.
About Legend Biotech
Legend Biotech is a global biotechnology company dedicated to treating, and one day curing, life-threatening diseases. Headquartered in Somerset, New Jersey, we are developing advanced cell therapies across a diverse array of technology platforms, including autologous and allogenic chimeric antigen receptor T-cell and natural killer (NK) cell-based immunotherapy. From our three R&D sites around the world, we apply these innovative technologies to pursue the discovery of cutting-edge therapeutics for patients worldwide.
An email has been sent to your address with instructions for changing your password.
There is no user registered with this email.
Sign Up
To create a free account, please fill out the form below.
Thank you for signing up!
A confirmation email has been sent to your email address. Please check your email and follow the instructions in the message to complete the registration process. If you do not receive the email, please check your spam folder or contact us for assistance.
Welcome to our platform!
Oops!
Something went wrong while trying to create your new account. Please try again and if the problem persist, Email Us to receive support.